Empyrean Grabs $22M to Target CNS Disorders with Plant-Based Platform 0 18.10.2022 03:00 Feedity.com Genetic engineering company Empyrean Neurosciences stepped into the CNS arena with $22 million and a small molecule platform derived from plants and fungi. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
